Metastasis suppressors regulate the tumor microenvironment by blocking recruitment of prometastatic tumor-associated macrophages

Cancer Research

Volumn 75, Issue 19, 2015, Pages 4063-4073

  Frankenberger, Casey ^a   Rabe, Daniel ^a   Bainer, Russell ^b   Sankarasharma, Devipriya ^c   Chada, Kiran ^c   Krausz, Thomas ^b   Gilad, Yoav ^b   Becker, Lev ^a   Rosner, Marsha Rich ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROPHAGE CHEMOTACTIC FACTOR; MARAVIROC; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN HMGA2; PROTEIN PRGN; RANTES; REGULATOR PROTEIN; RNA; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; CCL5 PROTEIN, HUMAN; CCL5 PROTEIN, MOUSE; CCR5 PROTEIN, MOUSE; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CYCLOHEXANE DERIVATIVE; HIGH MOBILITY GROUP A2 PROTEIN; MESSENGER RNA; PEBP1 PROTEIN, HUMAN; RAF KINASE INHIBITORY PROTEIN, MOUSE; TRIAZOLE DERIVATIVE; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INVASION; CELL ISOLATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY MECHANISM; RNA SEQUENCE; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CHEMOTAXIS; DISEASE FREE SURVIVAL; DRUG EFFECTS; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; GENETICS; IMMUNOLOGY; MACROPHAGE; MAMMARY NEOPLASMS, EXPERIMENTAL; METASTASIS; MORTALITY; NUDE MOUSE; PHYSIOLOGY; SEQUENCE ANALYSIS; TRANSPLANTATION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CHEMOKINE CCL5; CHEMOKINES; CHEMOTAXIS; CYCLOHEXANES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HMGA2 PROTEIN; HUMANS; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RECEPTORS, CCR5; RNA, MESSENGER; RNA, NEOPLASM; SEQUENCE ANALYSIS, RNA; TRIAZOLES; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84940947550     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3394     Document Type: Article

References (38)

1. Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, et al. Cancer Statistics Review, 1975-2011-SEER Satistics. SEER Cancer Statistics Review 2011. Available from: http://seer.cancer.gov/csr/1975-2011/.
2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
3. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009;9:S73-81.
4. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.
5. Tchou J, Conejo-Garcia J. Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. Advances in pharmacology 2012;65:45-61.
6. Zeng L, Imamoto A, Rosner MR. Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opin Ther Targets 2008;12:1275-87.
7. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, et al. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 2003;95:878-89.
8. Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J 2009;28:347-58.
9. Yun J, Frankenberger CA, Kuo WL, Boelens MC, Eves EM, Cheng N, et al. Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J 2011;30:4500-14.
10. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, et al. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol 2001;21:7207-17.
11. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013;496:445-55.
12. Agarwal S, Gertler FB, Balsamo M, Condeelis JS, Camp RL, Xue X, et al. Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer. Breast Cancer Res 2012; 14:R124.
13. Joyce JA, Pollard JW.Microenvironmental regulation ofmetastasis. Nat Rev Cancer 2009;9:239-52.
14. Green CE, Liu T, Montel V, Hsiao G, Lester RD, Subramaniam S, et al. Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS ONE 2009;4:e6713.
15. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013;23:277-86.
16. Meissner F, Scheltema RA, Mollenkopf HJ, Mann M. Direct proteomic quantification of the secretome of activated immune cells. Science 2013; 340:475-8.
17. Medrek C, Ponten F, Jirstrom K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 2012;12:306.
18. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238-46.
19. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475:222-5.
20. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003;63:8360-5.
21. Lu H, Clauser KR, Tam WL, Frose J, Ye X, Eaton EN, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol 2014;16:1105-17.
22. Su S, Liu Q, Chen J, Chen J, Chen F, He C, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 2014;25:605-20.
23. Hijikata A, Kitamura H, Kimura Y, Yokoyama R, Aiba Y, Bao Y, et al. Construction of an open-access database that integrates cross-reference information from the transcriptome and proteome of immune cells. Bioinformatics 2007;23:2934-41.
24. Peach RJ, Bajorath J, Naemura J, Leytze G, Greene J, Aruffo A, et al. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T-cell surface receptors CTLA-4 and CD28. J Biol Chem 1995;270:21181-7.
25. Dols A,Smith JWII, Meijer SL, Fox BA,HuHM, Walker E, et al.Vaccinationof women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Human Gene Therapy 2003;14:1117-23.
26. Stavik B, SkrettingG, Aasheim HC, TinholtM, Zernichow L, Sletten M, et al. Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility. BMC Cancer 2011;11:357.
27. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-63.
28. Velasco-Velazquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 2012;72:3839-50.
29. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988; 55:619-25.
30. Lehmann BD, Bauer JA, Chen X, SandersME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-67.
31. Huang daW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols 2009;4:44-57.
32. Grote VA, Kaaks R, Nieters A, Tjonneland A, Halkjaer J, Overvad K, et al. Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br J Cancer 2012;106: 1866-74.
33. Dossus L, Becker S, Rinaldi S, Lukanova A, Tjonneland A, Olsen A, et al. Tumor necrosis factor (TNF)-alpha, soluble TNF receptors and endometrial cancer risk: the EPIC study. Int J Cancer 2011;129:2032-7.
34. Gross AL, Newschaffer CJ, Hoffman-Bolton J, Rifai N, Visvanathan K. Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev 2013;22:1319-24.
35. He Z, Ismail A, Kriazhev L, Sadvakassova G, Bateman A. Progranulin (PCcell-derived growth factor/acrogranin) regulates invasion and cell survival. Cancer Res 2002;62:5590-6.
36. Tangkeangsirisin W, Serrero G. PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells. Carcinogenesis 2004;25:1587-92.
37. He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cellderived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med 2003;81:600-12.
38. Ho JC, Ip YC, Cheung ST, Lee YT, Chan KF, Wong SY, et al. Granulinepithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 2008;47:1524-32.